Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Amgen Inc. is conducting a study titled ‘Real World Evaluation of Sotorasib Among Chinese Non-Small Cell Lung Cancer Patients.’ The study aims to assess the safety profile of sotorasib, a drug designed for patients with KRAS p.G12C-mutated non-small cell lung cancer (NSCLC) who have undergone prior systemic therapy. This research is significant as it provides real-world insights into the drug’s safety among Chinese patients, potentially influencing treatment protocols and patient outcomes.
The intervention being tested is sotorasib, an oral medication taken daily by participants until disease progression or unacceptable toxicity occurs. Sotorasib targets specific mutations in cancer cells, aiming to halt or slow the progression of NSCLC.
This observational study follows a cohort model with a retrospective time perspective. It does not involve random allocation or masking, focusing instead on real-world data collection from patients who have already received the treatment.
The study began on August 20, 2025, with the latest update submitted on September 10, 2025. These dates are crucial as they mark the study’s initiation and the most recent information available, indicating ongoing recruitment and data collection efforts.
Market implications of this study update could be significant for Amgen’s stock performance, as positive safety data might enhance investor confidence and strengthen the company’s position in the oncology market. Given the competitive landscape of cancer treatments, successful outcomes could differentiate sotorasib from similar offerings by competitors.
The study is currently recruiting, with further details available on the ClinicalTrials portal.